Biotherapeutics for the Prevention of Clostridium difficile Infection
Experts review biotherapeutics for the prevention of C difficile infection, including probiotics, fecal microbiota transplantation, and nontoxigenic C difficile.
Experts review biotherapeutics for the prevention of C difficile infection, including probiotics, fecal microbiota transplantation, and nontoxigenic C difficile.
Experts review novel antibiotic therapies that may limit the impact on the gut microbiome, as well as passive immunization products that may bolster the immune response to C difficile toxins and possibly reduce the frequency of toxigenic strains.
Drs Kociolek and Shulman, from the division of infectious diseases at the Ann & Robert H. Lurie Children’s Hospital of Chicago in Illinois, review all the current vaccine candidates in development for Clostridium difficile infection.